GenMark Diagnostics, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular diagnostic testing systems based on its proprietary eSensor detection technology in the United States. The company develops XT-8 system, an automated molecular diagnostic system consisting of a compact bench-top workstation and self-contained disposable test cartridges enabling reference laboratories and hospitals to perform a range of molecular diagnostic tests. It also offers 6 diagnostic tests for use with its XT-8 system that include Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity Test that determines an individual's ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual's increased risk of blood clots; Respiratory Viral Panel Test that covers approximately 20 viruses, including influenza A, influenza B, respiratory syncytial virus, and various other upper respiratory viruses; 2C19 Genotyping Test, which is used for the detection and genotyping of various alleles of the cytochrome P450 (CYP450) 2C19 gene locus; and Hepatitis C Virus Genotyping Test, a test for the detection and typing/subtyping of HCV. In addition, the company engages in developing a NexGen system by integrating automated nucleic acid extraction and amplification capabilities with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.